智飞生物：CA111注射液进入Ⅰ期临床试验

Core Viewpoint - The company Zhifei Biological (300122.SZ) has announced that its subsidiary, Chongqing Chen'an Biological Pharmaceutical Co., Ltd., has initiated Phase I clinical trials for the CA111 injection in Zhejiang Province [1] Group 1: Product Development - The CA111 injection is a dual agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors [1] - GIP is a 42-amino acid gastrointestinal regulatory peptide that stimulates insulin secretion from pancreatic beta cells in the presence of glucose and protects these cells, playing a physiological role in glucose homeostasis [1] - GLP-1 is a 37-amino acid peptide that stimulates insulin secretion, protects pancreatic beta cells, and inhibits glucagon secretion, gastric emptying, and food intake, thereby controlling blood sugar and body weight [1] - The dual receptor agonist approach of GIP and GLP-1 can achieve synergistic effects, leading to better glucose-lowering and weight loss outcomes compared to single-target drugs, while effectively reducing side effects [1]